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CASE REPORT

Tissue plasminogen activator (tPA) treatment for COVID-19
associated acute respiratory distress syndrome (ARDS): A case
series
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Abstract
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A prothrombotic coagulopathy is commonly found in critically ill COVID-19 patients
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with acute respiratory distress syndrome (ARDS). A unique feature of COVID-19 respiratory failure is a relatively preserved lung compliance and high Alveolar-arterial
oxygen gradient, with pathology reports consistently demonstrating diffuse pulmo-
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nary microthrombi on autopsy, all consistent with a vascular occlusive etiology of res-
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COVID-19 pandemic is overwhelming the world’s medical care capacity with unprec-
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piratory failure rather than the more classic findings of low-compliance in ARDS. The
edented needs for mechanical ventilators and high rates of mortality once patients
progress to needing mechanical ventilation, and in many environments including in
parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality
and marked improvements in oxygenation. Here we report a series of three patients
with severe COVID-19 respiratory failure who were treated with tissue plasminogen
activator. All three patients had a temporally related improvement in their respiratory
status, with one of them being a durable response.
KEYWORDS

acute respiratory distress syndrome (ARDS), case report, COVID-19, fibrinolysis, tissue
plasminogen activator (tPA)
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1 | I NTRO D U C TI O N

elevated D-dimer, the decision was made to administer tPA
(Alteplase) 25 mg intravenously over 2 hours, followed by a 25 mg

A hallmark of severe COVID-19 is coagulopathy, with 71.4% of

tPA infusion over the subsequent 22 hours. The patient tolerated

patients who die of COVID-19 meeting International Society on

tPA therapy without bleeding or any other apparent complication.

Thrombosis and Haemostasis criteria for disseminated intravascu-

Eleven hours into his tPA infusion his P/F ratio had improved to 408,

lar coagulation (DIC), whereas only 0.6% of patients who survive

a twofold improvement from pre-tPA. Following completion of the

meet these criteria.1 Additionally, it has become clear that this is

tPA infusion, a heparin infusion was started at 10 units/kg/h with a

not a bleeding diathesis but rather a predominantly prothrombotic

partial thromboplastin time goal of 60 to 80. One hour into his hep-

DIC with high venous thromboembolism rates, elevated D-dimer

arin infusion, his P/F ratio worsened to 136. There was a concern

levels, high fibrinogen levels in concert with low antithrombin lev-

for fluid overload and pulmonary edema given he was 1 L positive

els, and pulmonary congestion with microvascular thrombosis and

on his fluid balance for the prior 24 hours and remained anuric on

occlusion on pathology in addition to mounting experience with

CRRT, but efforts to remove volume via CRRT were complicated by

high rates of central line thrombosis and vascular occlusive events

the development of rapid atrial fibrillation and hypotension, which

(eg, ischemic limbs, strokes) observed by those who care for criti-

made it difficult to achieve a negative fluid balance. His vasopres-

cally ill COVID-19 patients.1-7 There is evidence in both animals and

sor requirements increased from one to three (norepinephrine, phe-

humans that fibrinolytic therapy in acute lung injury and acute re-

nylephrine, and vasopressin). At 48 hours post-tPA, his P/F was 188

spiratory distress syndrome (ARDS) improves survival, which also

to 250, similar to his pre-tPA status. His fibrinogen levels remained

points to fibrin deposition in the pulmonary microvasculature as a

similar at 351 mg/dL and his D-dimer had decreased to 16 678 ng/

contributory cause of ARDS. This would be expected to be seen

mL. Unfortunately, by HD 11, the patient continued to descend into

in patients with ARDS and concomitant diagnoses of DIC on their

multiple organ failure with refractory hypotension secondary to ar-

laboratory values such as what is observed in more than 70% of

rhythmia and superimposed bacterial infection. He was made do

those who die of COVID-19.

8-10

The following are three case re-

not resuscitate and expired shortly after.

ports of using tissue plasminogen activator (tPA) in critically ill, mechanically ventilated COVID-19 positive patients with ARDS where
extracorporeal membrane oxygenation capabilities, staffing, and

1.2 | Case 2

resources are extremely limited as a result of the current COVID19 pandemic.

A 59-year-old female with a history of hypertension presented to
an outside hospital after 2 days of rhinorrhea, cough, myalgias, and

1.1 | Case 1

headaches. Vital signs from her initial presentation at the outside
hospital are not available. A CT scan of the chest demonstrated
bibasilar predominantly ground-glass opacities, and COVID-19 test-

A 75-year-old male with a history of hypertension, hyperlipidemia,

ing was positive. Hydroxychloroquine and azithromycin were initi-

type 2 diabetes mellitus, and coronary artery disease presented to

ated. Her oxygen requirement progressed over 2 days from nasal

the hospital with 1 week of cough, fatigue, and fevers. Vital signs

cannula O2 supplementation to 100% NRB with a partial pressure

on presentation were temperature, 38.5°C; heart rate, 87 beats/

of oxygen of 137. On HD 4, she required intubation for hypoxemic

min; blood pressure, 133/78 mm Hg; respiratory rate 22, oxygen

respiratory failure and was transferred to our hospital. She required

saturation (SpO2) 91% on room air. Computed tomography (CT)

one vasopressor for hemodynamic support and chemical paralysis

scan of the chest revealed bilateral ground-glass opacities with

in addition to sedation. Her P/F ratio was 82 supine and improved

peripheral and basilar predominance; COVID-19 testing was posi-

to the 130s in the prone position. On return to supine position, her

tive. Hydroxychloroquine and azithromycin were started and given

P/F ratio dropped back to as low as 90. On HD 6, her D-dimer was

for 5 days. His oxygen requirement increased from 4 to 6 L/min

545 ng/mL; this increased to 20 293 ng/mL by HD 9 with a fibrino-

O2 supplementation on day of admission to 100% fraction of in-

gen level of 939 mg/dL. After 4 days of being intubated and 2 days in

spired oxygen (FiO2) on a non-rebreather mask (NRB) by day 3, with

the prone position with no durable improvements, IV tPA (Alteplase)

SpO2 improving from 85% to 91% with positioning in the awake

was administered as a 25-mg intravenous bolus over 2 hours, fol-

prone position. Unfortunately, his severe hypoxemia persisted and

lowed by a 25-mg tPA infusion over the subsequent 22 hours. The

he was intubated on hospital day (HD) 6 at which time his partial

patient tolerated tPA therapy and was transitioned to heparin ther-

pressure of oxygen/FiO2 (P/F) ratio was 73. His FiO2 requirements

apy (as in Case 1) without any bleeding complications. At 4 hours

remained >60% despite maximal ventilatory strategies, his D-dimer

after completing tPA, her P/F was 135 (prone position), which was

levels were consistently >50 000 ng/mL for the 4 days following

similar to pre-tPA, but by 12 hours after completing tPA, her P/F

his intubation and his fibrinogen levels ranged between 375 and

ratio had improved to 150 (prone position) with D-dimer increased

541 mg/dL. On HD 8, his P/F ratio ranged between 140 and 240

to 40 490 ng/mL. By 38 hours after completing the tPA infusion,

and he became anuric, for which he was initiated on continuous

the patient continued to improve and was placed back in the supine

renal replacement therapy (CRRT); that combined with persistently

position where the P/F ratio was now 135, a 50% improvement in

|
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supine position P/F ratio compared with the P/F of 90 in the supine

by 1.2%.11 Such an approach using larger bolus dose tPA (50- or

position 3 days earlier.

100-mg bolus) without holding anticoagulation to prevent recurrence of the suspected pulmonary microvascular thrombosis un-

1.3 | Case 3

derlying COVID-19 ARDS7 is worthy of further consideration and
study, and although the mortality in COVID-19 ARDS is exceptionally high, the risks of tPA must still be carefully considered given

A 49-year-old male with no known medical history presented with

the ~1% risk of catastrophic bleeding from tPA in nonstroke pa-

6 days of cough, progressive dyspnea, fever, and myalgias. Vital signs

tients.11,12 Formal studies are needed to determine whether the

on presentation were temperature, 36.5°C; heart rate, 133 beats/

observations in these cases were the result of tPA therapy or the

min; blood pressure, 115/74 mm Hg; and a respiratory rate of 24.

result of unrelated/random effects, and (if effective) to determine

SpO2 was 40% on room air in the emergency department and im-

the optimal dosing regimen of tPA with or without therapeutic an-

proved to 90% on 100% FiO2 via NRB; however, given increased

ticoagulation in COVID-19 ARDS to include whether a redosing

tachypnea, he was intubated and required one vasopressor for

protocol is needed if the benefits are transient.

hemodynamic support, sedation, and chemical paralysis. A CT scan
of the chest was performed and revealed bibasilar ground-glass

C O N FL I C T O F I N T E R E S T

opacities. Positive end-expiratory pressure of 20 was initially used;

CD Barrett, HB Moore, EE Moore, and MB Yaffe have patents

however, he developed pneumopericardium and thus his positive

pending related to both coagulation/fibrinolysis diagnostics and

end-expiratory pressure was reduced. Hydroxychloroquine and

therapeutic fibrinolytics, and are passive cofounders and hold stock

azithromycin were started as well as heparin drip for suspicion of

options in Thrombo Therapeutics, Inc. HB Moore and EE Moore

venous thromboembolism. On HD 1, his D-dimer was 33 228 ng/
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mL; on HD 2, it had reduced to 17 301 ng/mL. His P/F ratio was 120

Laboratories. MB Yaffe has previously received a gift of Alteplase

in the prone position, and in the supine position his P/F ratio ranged

(tPA) from Genentech, and owns stock options as a cofounder of

from 72 to 90. His heparin drip was held and IV tPA (Alteplase) was
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administered similarly to as in cases 1 and 2, with the heparin drip re-
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suming immediately after completion of the tPA infusion. His supine
P/F improved from 72 to 90 pre-tPA to a P/F of 125 by 3 hours after

AU T H O R C O N T R I B U T I O N S

completion of tPA, a 38% to 73% increase. There were no bleed-

J Wang, N Hajizadeh, and CD Barrett prepared the manuscript with

ing complications. After tPA, his D-dimer increased from 17 301 to

critical input and revisions from EE Moore, RC McIntyre, PK Moore,

37 215 ng/mL and his fibrinogen decreased from 874 mg/dL (pre-
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tPA) to 544 mg/dL (35 hours post-tPA). By 33 hours after completing
the tPA infusion, his P/F ratio declined to 71 and the patient was
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placed back in the prone position with recovery to a P/F ratio of 118.

Christopher D. Barrett

2 | D I S CU S S I O N
In summary, we now report three cases of off-label intravenous
administration of tPA (Alteplase) for patients with COVID-19 suffering from ARDS and respiratory failure. In all three cases, the
patients demonstrated an initial improvement in their P/F ratio,
with improvements ranging from a 38% improvement (case 3)
to a ~100% improvement (case 1). The observed improvements
were durable in one patient but transient and lost over time in
two patients after completion of their tPA infusion. In the study by
Hardaway et al using fibrinolytic therapy in ARDS, they redosed
the fibrinolytic agent in patients who had transient responses
such as were observed in two of the three patients here, which
led to more durable responses. 8 There is also precedent for using
much larger bolus doses of tPA and doing so while patients remain on a therapeutic heparin drip, such as in submassive pulmonary embolism where the use of a 100-mg bolus of tPA (Alteplase)
while on a therapeutic heparin drip has been shown to be highly
effective in reducing mortality and only increases bleeding risk

https://orcid.org/0000-0001-9720-8155
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